Article
Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
Experimental cell research - 15 Aug 2014
Yasugi Masayuki, Takigawa Nagio, Ochi Nobuaki, Ohashi Kadoaki, Harada Daijiro, Ninomiya Takashi, Murakami Toshi, Honda Yoshihiro, Ichihara Eiki, Tanimoto Mitsune, Kiura Katsuyuki
Abstract excerpt
Everolimus is an orally administered mTOR inhibitor. The effect, and mechanism of action, of everolimus on lung cancers with an epidermal growth factor receptor (EGFR) mutation remain unclear. Four gefitinib-sensitive and -resistant cell lines were used in the present work. Growth inhibition was determined using the MTT assay. Transgenic mice carrying the EGFR L858R mutation were treated with everolimus (10...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.